Testosterone in men's health: a new role for an old hormone

Journal of Men's Health

Volumn 6, Issue 3, 2009, Pages 169-176

  Feeley, Robert J ^a   Saad, Farid ^b   Guay, Andre ^c   Traish, Abdulmaged M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYER PHARMA AG   (Germany)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Androgen deficiency; Diabetes; Dyslipidemia; Erectile dysfunction; Metabolic syndrome; Obesity; Testosterone; Vascular disease

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; RISK REDUCTION; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM;

EID: 69949176406     PISSN: 18756867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jomh.2009.06.005     Document Type: Review

References (97)

1. Taskinen M.R. Is metabolic syndrome the main threat to human health in the twenty-first century?. Arterioscler Thromb Vasc Biol 27 (2007) 2275
2. Bataille V., Perret B., Dallongeville J., Arveiler D., Yarnell J., Ducimetiere P., et al. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. Diabetes Metab 32 (2006) 475-479
3. Imam S.K., Shahid S.K., Hassan A., and Alvi Z. Frequency of the metabolic syndrome in type 2 diabetic subjects attending the diabetes clinic of a tertiary care hospital. J Pak Med Assoc 57 (2007) 239-242
4. Rodriguez A., Muller D.C., Metter E.J., Maggio M., Harman S.M., Blackman M.R., et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92 (2007) 3568-3572
5. Muller M., Grobbee D.E., den Tonkelaar I., Lamberts S.W., and van der Schouw Y.T. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90 (2005) 2618-2623
6. Kupelian V., Page S.T., Araujo A.B., Travison T.G., Bremner W.J., and McKinlay J.B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91 (2006) 843-850
7. Kupelian V., Shabsigh R., Araujo A.B., O'Donnell A.B., and McKinlay J.B. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 176 (2006) 222-226
8. Miner M.M., and Sadovsky R. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Clin J Med 74 (2007) S38-S46
9. Miner M.M., and Seftel A.D. Testosterone and aging: what we have learned since the Institute of Medicine and what lies ahead. Int J Clin Prac 61 (2007) 622-632
10. Blouin K., Despres J.P., Couillard C., Tremblay A., Prud'homme D., Bouchard C., et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54 (2005) 1034-1040
11. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Valkonen V.P., et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90 (2005) 712-719
12. Kaplan S.A., Meehan A.G., and Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol 176 (2006) 1524-1528
13. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Salonen R., et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149 (2003) 601-608
14. Pasquali R., Macor C., Vicennati V., Novo F., De Lasio R., Mesini P., et al. Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism 46 (1997) 526-529
15. Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 19 (2007) 124-128
16. Osuna J.A., Gomez-Perez R., Arata-Bellabarba G., and Villaroel V. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl 52 (2006) 355-361
17. Svartberg J., von Muhlen D., Sundsfjord J., and Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromso Study. Eur J Epidemiol 19 (2004) 657-663
18. Isidori A.M., Caprio M., Strollo F., Moretti C., Frajese G., Isidori A., et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 84 (1999) 3673-3680
19. Rosmond R., Wallerius S., Wanger P., Martin L., Holm G., and Bjorntorp P. A 5 year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med 254 (2003) 386-390
20. Kalyani R.R., and Dobs A.S. Androgen deficiency, diabetes and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 14 (2007) 226-234
21. D'Amico A.V., Denham J.W., Crook J., Chen M.H., Goldhaber S.Z., Lamb D.S., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction. J Clin Oncol 25 (2007) 2420-2425
22. Braga-Basaria M., Dobs A.S., Muller D.C., Carducci M.A., John M., Egan J., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
23. Chen Z., Maricic M., Nguyen P., Ahmann F.R., Bruhn R., and Dalkin B.L. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95 (2002) 2136-2144
24. Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A.L., Fallon M.A., Schoenfeld D.A., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 (2002) 599-603
25. Smith M.R., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 (2006) 1305-1308
26. Yialamas M.A., Dwyer A.A., Hanley E., Lee H., Pitteloud N., and Hayes F.J. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92 (2007) 4254-4259
27. Lee S.J., Gungor N., Bacha F., and Arslanian S. Insulin resistance: link to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth. Diabetes Care 30 (2007) 2091-2097
28. Katznelson L., Finkelstein J.S., Schoenfeld D.A., Rosenthal D.I., Anderson E.J., and Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81 (1996) 4358-4365
29. Tenover J.S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75 (1992) 1092-1098
30. Swerdloff R.S., and Wang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 6 (2003) 207-211
31. Wang C., Cunningham G., Dobs A., Iranmanesh A., Matsumoto A.M., Snyder P.J., et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89 (2004) 2085-2098
32. Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16 (1992) 991-997
33. Boyanov M.A., Boneva Z., and Christov V.G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6 (2003) 1-7
34. Kapoor D., Goodwin E., Channer K.S., and Jones T.H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154 (2006) 899-906
35. Parikh N.I., Pencine M.J., Wang T.J., Lanier K.J., Fox C.S., d'Agostino R.B., et al. Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med 120 (2007) 242-250
36. Steinbrook R. Facing the diabetes epidemic - mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 354 (2006) 545-548
37. Ford E.S., Li C., Zhao G., Pearson W.S., and Mokdad A.H. Prevalence of the metabolic syndrome among US adolescents using the definition from the international diabetes federation. Diabetes Care 31 (2008) 587-589
38. Haffner S.M., Miettinen H., Karhapa P., Mykkanen L., and Laakso M. Leptin concentrations, sex hormones, and cortisol in nondiabetic men. J Clin Endocrinol Metab 82 (1997) 1807-1809
39. Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., and McKinlay J.B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 23 (2000) 490-494
40. Oh J.Y., Barrett-Connor E., Wedick N.M., and Wingard D.L. Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabetes Care 25 (2002) 55-60
41. Rhoden E.L., Ribeiro E.P., Teloken C., and Souto C.A. Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 96 (2005) 867-870
42. Shores M.M., Matsumoto A.M., Sloan K.L., and Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med 166 (2006) 1660-1665
43. Selvin E., Feinleib M., Zhang L., Rohrmann S., Rifai N., Nelson W., et al. Androgens and diabetes in men. Diabetes Care 30 (2007) 234-238
44. Ding E.L., Song Y., Malik V.S., and Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295 (2006) 1288-1299
45. Simon D., Charles M.A., Nahoul K., Orssaud G., Kremski J., Hully V., et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 82 (1997) 682-685
46. Pitteloud N., Hardin M., Dwyer A.A., Valassi E., Yialamas M., Elahi D., et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90 (2005) 2636-2641
47. Pitteloud N., Mootha V.K., Dwyer A.A., Hardin M., Lee H., Eriksson K.F., Tripathy D., et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28 (2005) 1636-1642
48. Basaria S., Muller D.C., Carducci M.A., Egan J., and Dobs A.S. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 (2006) 581-588
49. Lage M.J., Barber B.L., and Markus R.A. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70 (2007) 1104-1108
50. Haidar A., Yassin A., Saad F., and Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 10 (2007) 189-196
51. Dhindsa S., Prabhakar S., Sethi M., Bandyopadhyay A., Chaudhuri A., and Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 5462-5468
52. Kapoor D., Aldred H., Clark S., Channer K., and Jones T. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care 30 (2007) 911-917
53. Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Morselli Labate A.M., Fabbri R., et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 40 (1991) 101-104
54. Pagotto U., Gambineri A., Pelusi C., Genghini S., Cacciari M., Otto B., et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab 88 (2003) 4139-4143
55. Naharci M.I., Pinar M., Bolu E., and Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonaidsm. Endocr Pract 13 (2007) 629-635
56. Hutson J.C., Stocco D.M., Campbell G.T., and Wagoner J. Sertoli cell function in diabetic, insulin-treated diabetic, and semi-starved rats. Diabetes 32 (1983) 112-116
57. Wabitsch M., Blum W.F., Muche R., Braun M., Hube F., Rascher W., et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest 100 (1997) 808-813
58. Maggio M., Blackford A., Taub D., Carducci M., Ble A., Metter E.J., et al. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 27 (2006) 725-728
59. Maggio M., Lauretani F., Ceda G.P., Bandinelli S., Ling S.M., Metter E.J., et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 167 (2007) 2249-2254
60. Khaw K., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116 (2007) 2694-2701
61. Carrero J.J., Qureshi A.R., Parini P., Arver S., Lindholm B., Barany P., et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 20 3 (2009) 613-620
62. Laughlin G.A., Barrett-Connor E., and Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93 (2008) 68-75
63. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 29 (2008) 534-539
64. Smith G., Ben-Shlomo Y., Beswick A., Yarnell J., Lightman S., and Elwood P. Cortisol, testosterone, and coronary heart disease prospective evidence from the Caperhill Study. Circulation 112 (2005) 332-340
65. Hak A., Witteman J., de Jong F., Geerlings M., Hofman A., and Pols H. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87 (2002) 3632-3639
66. Phillips G., Pinkernell B., and Jing T. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 14 (1994) 701-706
67. Dunajska K., Milewicz A., Szymczak J., Jedrzejuk D., Kuliczkowski W., Salomon P., et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male 7 (2004) 197-204
68. Makinen J.I., Perheentupa A., Irjala K., Pollanen P., Makinen J., Huhtaniemi I., et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 197 (2008) 688-693
69. Traish A.M., Guay A.T., Feeley R., and Saad F. The dark side of testosterone deficiency: I. metabolic syndrome and erectile dysfunction. J Androl 30 (2009) 10-22
70. Traish A.M., Saad F., and Guay A.T. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30 (2009) 23-32
71. Traish AM, Saad F, Guay AT. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009 Apr 2.[Epub ahead of print].
72. Smith M.R., Bennett S., Evans L., Kynaton H., Parmar M., Mason M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 (2001) 4261-4267
73. Zitzmann M., and Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92 (2007) 3844-3853
74. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
75. Dockery F., Bulpitt C.J., Agarwal S., Donaldson M., and Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 104 (2003) 195-201
76. Marin P., Holmang S., Gustafsson C., Jonsson L., Kvist H., Elander A., et al. Androgen treatment of abdominally obese men. Obesity Res 1 (1993) 245-251
77. Page S.T., Amory J.K., Bowman F.D., Anawalt B.D., Matsumoto A.M., Bremner W.J., et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serium T. J Clin Endocrinol Metab 90 (2005) 1502-1510
78. Heufelder AE, Saad F, Bunck MC, Gooren L. 52-Week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J. Andrology 2009; in press.
79. Lu Y.L., Kuang L., Zhu H., Wu H., Wang X.F., Pang Y.P., et al. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5-alpha-reductase inhibitor. Asian J Androl 9 (2007) 843-847
80. Akishita M., Hashimoto M., Ohike Y., Ogawa S., Iijima K., Eto M., et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 30 (2007) 1029-1034
81. Foresta C., Caretta N., Lana A., De Toni L., Biagioli A., Ferlin A., et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrin Metab 91 (2006) 4599-4602
82. Malkin C.J., Pugh P.J., Morris P.D., Kerry K.E., Jones R.D., Jones T.H., et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90 (2004) 871-876
83. Malkin C.J., Pugh P.J., West J.N., van Beek E.J., Jones T.H., and Channer K.S. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27 (2006) 57-64
84. Webb C., Elkington A., Kraidly M., Keenan N., Pennell D., and Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 101 (2008) 618-624
85. Makinen J., Jarvisalo M., Pollanen P., Perheentupa A., Irjala K., Koskenvuo M., et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 45 (2005) 1603-1608
86. De Pergola G., Pannacciulli N., Ciccone M., Tartagni M., Rizzon P., and Giorgino R. Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. Int J Obes 27 (2003) 803-807
87. Stattin P., Lumme S., Tekanen L., Alfthan H., Jellum E., Hallmans G., et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108 (2004) 418-424
88. Travis R.C., Key T.J., Allen N.E., Appleby P.N., Roddam A.W., Rinaldi S., et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121 (2007) 1331-1338
89. Roddam A.W., Allen N.E., Appleby P., and Key T.J. Endogenous Hormones, Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100 (2008) 170-183
90. Malkin C.J., Pugh P.J., Jones R.D., Kapoor D., Channer K.S., and Jones T.H. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89 (2004) 3313-3318
91. Haffner S.M., Mykkanen L., Valdez R.A., and Katz M.S. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 77 (1993) 1610-1615
92. Pugh P.J., Jones T.H., and Channer K.S. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24 (2003) 909-915
93. Zmuda J.M., Cauley J.A., Kriska A., Glynn N.W., Gutai J.P., and Kuller L.H. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men: a 13 year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol 146 (1997) 609-617
94. Gyllenborg J., Rasmussen S., Borch-Johnsen K., Heitmann B.L., Skakkebaek N.E., and Juul A. Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism 50 (2001) 882-888
95. Dubey R.K., Oparil S., Imthurn B., and Jackson E.K. Sex hormones and hypertension. Cardiovasc Res 53 (2002) 688-708
96. Makhsida N., Shah J., Yan G., Fisch H., and Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174 (2005) 827-834
97. Haddad R.M., Kennedy C.C., Caples S.M., Tracz M.J., Bolona E.R., Sideras K., et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82 (2007) 29-39